Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D07BIK
|
|||
| Former ID |
DIB016422
|
|||
| Drug Name |
VEL-0230
|
|||
| Synonyms |
NC-2300; Osteoporosis therapy (oral), Velcura/Nippon Chemiphar
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Rheumatoid arthritis [ICD-11: FA20] | Phase 1 | [1] | |
| Company |
Nippon Chemiphar Co Ltd
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C14H24NNaO5
|
|||
| Canonical SMILES |
CC(C)CC(COCC(C)C)NC(=O)C1C(O1)C(=O)[O-].[Na+]
|
|||
| InChI |
1S/C14H25NO5.Na/c1-8(2)5-10(7-19-6-9(3)4)15-13(16)11-12(20-11)14(17)18;/h8-12H,5-7H2,1-4H3,(H,15,16)(H,17,18);/q;+1/p-1/t10-,11-,12-;/m0./s1
|
|||
| InChIKey |
SGAKODIXAHVUKL-LFELFHSZSA-M
|
|||
| CAS Number |
CAS 221144-20-3
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Cathepsin K (CTSK) | Target Info | Inhibitor | [2] |
| KEGG Pathway | Lysosome | |||
| Osteoclast differentiation | ||||
| Toll-like receptor signaling pathway | ||||
| Rheumatoid arthritis | ||||
| NetPath Pathway | TGF_beta_Receptor Signaling Pathway | |||
| RANKL Signaling Pathway | ||||
| IL2 Signaling Pathway | ||||
| Reactome | Collagen degradation | |||
| Degradation of the extracellular matrix | ||||
| Activation of Matrix Metalloproteinases | ||||
| Trafficking and processing of endosomal TLR | ||||
| MHC class II antigen presentation | ||||
| WikiPathways | RANKL/RANK Signaling Pathway | |||
| Osteoclast Signaling | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Velcura Therapeutics, Inc. to Begin Clinical Trials in Rheumatoid Arthritis Patients. Velcura Therapeutics, Inc. JANUARY 07, 2009. | |||
| REF 2 | Discovery and parallel synthesis of a new class of cathepsin K inhibitors. Bioorg Med Chem Lett. 2001 Nov 19;11(22):2951-4. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.